|
|
|
|
|
| Caires,A.; Fernandes,G.S.; Leme,A.M.; Castino,B.; Pessoa,E.A.; Fernandes,S.M.; Fonseca,C.D.; Vattimo,M.F.; Schor,N.; Borges,F.T.. |
| Cyclosporin-A (CsA) is an immunosuppressant associated with acute kidney injury and chronic kidney disease. Nephrotoxicity associated with CsA involves the increase in afferent and efferent arteriole resistance, decreased renal blood flow (RBF) and glomerular filtration. The aim of this study was to evaluate the effect of Endothelin-1 (ET-1) receptor blockade with bosentan (BOS) and macitentan (MAC) antagonists on altered renal function induced by CsA in normotensive and hypertensive animals. Wistar and genetically hypertensive rats (SHR) were separated into control group, CsA group that received intraperitoneal injections of CsA (40 mg/kg) for 15 days, CsA+BOS and CsA+MAC that received CsA and BOS (5 mg/kg) or MAC (25 mg/kg) by gavage for 15 days. Plasma... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Genetically hypertensive rats; Acute kidney injury; Cyclosporine-A; Bosentan; Macitentan; Endothelin-1. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000200611 |
| |
|
|
| Fernandes,G.S.; Sternberg,C.; Lopes,G.; Chammas,R.; Gifoni,M.A.C.; Gil,R.A.; Araujo,D.V.. |
| A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, but it does allow the replication of similar molecules with the same activity. As biosimilars are about to be introduced in oncology practice, these must be evaluated through evidence-based medicine. This manuscript is a position paper, where the Brazilian Society of Clinical Oncology (SBOC) aims to describe pertinent issues regarding the approval and use of... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Immunobiologicals; Therapeutic antibodies; Biosimilar; Cancer management; Access. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000300401 |
| |
|
|
|
